Roche today announced positive new data from two global phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) at 24 weeks. Vabysmo met its primary endpoint in both studies and showed non-inferior visual acuity gains compared to aflibercept. More Vabysmo patients also showed an absence of blood vessel leakage in the retina compared to aflibercept, and if approved, RVO would be the third indication for Vabysmo.
A copy of the full press release can be found here:
https://www.roche.com/media/releases/med-cor-2023-02-10